4:11 PM
 | 
Nov 14, 2017
 |  BC Extra  |  Financial News

Venture Roundup: ImmusanT, Locus

On Tuesday, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million.

ImmusanT raised $40 million in a series C round led by new investor Arch Venture Partners, with participation...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >